ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2021 and some content may be unavailable. To unlock all content for 2021, please visit the archives.

Abstract: PO2268

Lipid Accumulation Product Index and CKD

Session Information

Category: CKD (Non-Dialysis)

  • 2101 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention

Authors

  • Park, Keun Hyung, Yonsei University College of Medicine, Seoul, Seoul, Korea (the Republic of)
  • Jung, Chan-Young, Yonsei University College of Medicine, Seoul, Seoul, Korea (the Republic of)
  • Han, Seung Hyeok, Yonsei University College of Medicine, Seoul, Seoul, Korea (the Republic of)
  • Yoo, Tae-Hyun, Yonsei University College of Medicine, Seoul, Seoul, Korea (the Republic of)
  • Kang, Shin-Wook, Yonsei University College of Medicine, Seoul, Seoul, Korea (the Republic of)
  • Park, Jung Tak, Yonsei University College of Medicine, Seoul, Seoul, Korea (the Republic of)
Background

Obesity, a well-known risk factor for chronic kidney disease (CKD), is generally assessed using body mass index (BMI). However, because BMI does not take body composition into account, it may not reflect the metabolic abnormalities associated with obesity. Recently, lipid accumulation product index (LAP) has been proposed to effectively recognize metabolic syndrome. Therefore, the association between LAP and risk of incident CKD was investigated in a general population cohort.

Methods

A total of 180,268 subjects without CKD, who participated in the Korean Genome and Epidemiology Study from 2001 to 2018, were analyzed. LAP was calculated as [waist(cm)−65] × triglyceride(mmol/l) for males and [waist(cm)−58] × triglyceride(mmol/l) for females. The association between LAP and CKD, defined as eGFR<60mL/min/1.73m2, was examined in the cross-sectional analysis. In the longitudinal analysis, the risk of incident CKD development was analyzed among 8,427 participants without CKD at baseline which was a subset of the main cohort.

Results

The mean age was 53.1±8.4 years, and 117,321 patients (65.1%) were female. Prevalent CKD was observed in 342 (0.6%), 707 (1.2%), and 1155 (1.9%) participants in the lowest, middle, and highest LAP tertile groups, respectively. In multivariate logistic regression analysis, a logarithmic increase in LAP was associated with a 47% increase in CKD odds ratio (OR 1.47; 95% CI, 1.35-1.61; P<0.001). When stratified into tertiles, the risk of CKD prevalence was significantly higher in the highest tertile (OR 2.05; 95% CI, 1.72-2.45; P<0.001), when compared to the lowest tertile. During a mean follow-up of 182 months, CKD occurred in 720 (8.5%) participants. In the multivariable Cox analysis, LAP was significantly related with incident CKD risk (per 1-log LAP, HR 1.20; 95% CI, 1.13-1.27; P<0.001). The risk of incident CKD was significantly higher in the highest tertile (HR 1.48; 95% CI, 1.32-1.65) than the lowest tertile.

Conclusion

Increase in LAP was associated with higher prevalence of CKD and elevated risk of incident CKD.